Miracle Mile Advisors LLC Purchases 93 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Miracle Mile Advisors LLC lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,603 shares of the medical research company’s stock after acquiring an additional 93 shares during the quarter. Miracle Mile Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,788,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in TMO. LaFleur & Godfrey LLC boosted its holdings in shares of Thermo Fisher Scientific by 9.1% in the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock worth $15,486,000 after buying an additional 2,488 shares during the last quarter. Brighton Jones LLC boosted its holdings in shares of Thermo Fisher Scientific by 28.9% in the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $71,877,000. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Finally, Cidel Asset Management Inc. boosted its holdings in shares of Thermo Fisher Scientific by 3.0% in the 4th quarter. Cidel Asset Management Inc. now owns 1,313 shares of the medical research company’s stock worth $683,000 after buying an additional 38 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.9%

TMO stock opened at $401.99 on Monday. The company has a current ratio of 1.66, a quick ratio of 1.29 and a debt-to-equity ratio of 0.59. The company’s 50 day moving average is $420.74 and its 200 day moving average is $495.68. The stock has a market cap of $151.75 billion, a price-to-earnings ratio of 24.32, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. Thermo Fisher Scientific Inc. has a 1-year low of $390.50 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. Thermo Fisher Scientific’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period in the prior year, the business earned $5.11 earnings per share. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Investors of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.09%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Citigroup cut their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Scotiabank dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating on the stock in a report on Friday, April 25th. Evercore ISI dropped their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Argus dropped their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Finally, Royal Bank of Canada dropped their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a report on Thursday, April 24th. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific currently has a consensus rating of “Moderate Buy” and an average price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.